SpringerProtocols: Abstract: Antisense Efficacy: Site-Restricted In Vivo and Ex Vivo Models

Antisense Efficacy: Site-Restricted In Vivo and Ex Vivo Models

By: Leonard M. Neckers², Daniel Geselowitz², Christine Chavany², Luke Whitesell², Raymond Bergan²

Abstract

Full Text

Download PDF (6642K)

In the laboratory, antisense oligodeoxynucleotides (ODN) have repeatedly demonstrated efficacy in modulating the expression of various genes, thus providing important insights into their roles in tumorigenesis or normal growth and development (1–3). Although attention has been focused recently on the development of antisense ODN as therapeutics for a variety of diseases, including cancer (4), systemic application of ODN to treat tumors other than those of the hematopoietic system presents several problems, not least of which is the ability of systemically administered antisense to reach distant tumor sites. This is particularly true when considering tumors of the central nervous system (CNS), such as glioblastomas and HIV-associated B-cell lymphomas. In this case, the blood-brain barrrer poses an additional obstacle to successful delivery of anionic ODN. On the other hand, the intractability of CNS tumors to standard chemotherapy makes them interesting candidates for antisense intervention. The first model system we will discuss mvolves direct mfusron of ODN into the CNS for the purpose of continuous perfusion of tumor cells.

Affiliation(s): (2) Clinical Pharmacology Branch, National Cancer Institute, Bethesda, MD

Book Title: Antisense Therapeutics

Series: Methods in Molecular Medicine | Volume: 1 | Pub. Date: Mar-25-1996 | Page Range: 47-56 | DOI: 10.1385/0-89603-305-8:47

Subject: Cell Biology

References

Download References

1.	Cohen, J S (1991) Chemically modified oligodeoxynucleotide analogs as regulators of viral and cellular gene expression, in Gene Regulation. Biology of Antisense RNA and DNA (Erickson, R. P. and Izant, J. G., eds.), Raven, New York, pp. 247–260.

2.	Goodchtld, J. (1989) Inhibition of gene expression by oligonucleotides, in Oligodeoxynucleotides Antisense Inhibitors of Gene Expression (Cohen, J. S, ed), Macmillan, London, pp 53–77.

3.	Neckers, L., Whitesell, L, Rosolen, A., and Geselowitz, D. A. (1992) Antisense inhibition of oncogene expression. CRC Crit. Rev Oncogenesis 3, 175–231.

4.	Zamecnik, P C (1991) Oligonucleotide based hybridization as a modulator of genetic message readout, in Prospects for Antisense Nucleic Acid Therapy of Cancer and AIDS (Wickstrom, E., ed.), Wiley-Liss, New York, pp. 1–6.

5.	Neckers, L.M. (1993) Cellular Internalization of oligodeoxynucleotides, in Antisense Research and Appllcations (Crooke, S. T. and Lebleu, B, eds.), CRC, Boca Raton, FL, pp. 451–460.

6.	Whitesell, L., Rosolen, A., and Neckers, L M (1991) In vivo modulation of N-myc expression by continuous perfusion with an antisense oligonucleotide Antisense Res Dev 1, 343–350.

7.	Srmons, M., Edelman, E. R., DeKeyser, J.-L., Langer, R, and Rosenberg, R. D (1992) Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo Nature 359, 67–70.

8.	Whttesell, L, Geselowitz, D., Chavany, C., Fahmy, B., Walbndge, S, Alger, J.R., and Neckers, L M (1993) Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides implications for therapeutic application within the central nervous system. Proc. Natl Acad SCi USA 90, 4665–4669

9.	Bass, N and Lundborg, P (1973) Postnatal development of bulk flow in the cerebrospinal fluid system of the albino rat clearance of carboxyl-(¹⁴C)inulin after intrathecal infusion Brain Res 52, 323–332.

10.	Agrawal, S, Temsamam, J, and Tang, Y T. (1991) Pharmacokmettcs, bio-distribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Set USA 88, 7595–7599.

11.	Poplack, D. G and Riccardi, R (1987) The role of pharmacology in pediatric oncology, in The Role of Pharmacology in Pediatrie Oncology (Poplack, D G., Massimo, L, and Cornagha-Ferraris, P., eds.), Martinus Nijhoff, Boston, pp 137–156.

12.	Blaney, S. M., Balis, F.M., and Poplack, D. G. (1991) Pharmacologic approaches to the treatment of meningeal malignancy. Oncology 5, 107–116.

13.	Machado, M, Salcman, M, Kaplan, R.S, and Montgomery, E (1985) Expanded role of the cerebrospinal fluid reservoir in neurooncology: indications, causes of revision, and complications. Neurosurgery 17, 600–603

14.	Sundaresan, N and Suite, N. D. A (1989) Optimal use of the omaya reservoir in clinical oncology. Oncology 3, 15–22

15.	Urch, C, George, A, Stevenson, G, Bolognesi, A, Stirpe, F, Weller, R, and Glennie, M (1991) Intra-thecal treatment of leptomeningeal lymphoma with immunotoxin Int J Cancer 47, 909–915

16.	Moseley, R P., Papanastassiou, V, Zalutsky, M R, Ashpole, R. D., Evans, S., Bigner, D.D, and Kemshead, J.T. (1992) Immunoreactivny, pharmacokinetics and bone marrow dosimetry of intrathecal radioimmunoconjugates. Int J Cancer 52, 38–43

17.	List, J., Moser, R. P., Steuer, M., Loudon, W. G, Blacklock, J. B, and Grimm, E. A(1992) Cytokine responses to intraventricular injection of interleukin 2 into patients with leptomeningeal carcinomatosis rapid induction of tumor necrosts factor alpha, interleukin 1 beta, interleukin 6, gamma-Interferon, and soluble mterleukin 2 receptor (M, 55,000 protein). Cancer Res 52, 1123–1128

18.	Pluda, J. M., Yarchoan, R, Jaffe, E. S, Feurstem, I. M., Solomon, D., Steinberg, S M, Wyvill, M., Raubnschek, A, Katz, D, and Broder, S. (1990) Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on longterm antiretroviral therapy Ann Intern Med 113, 276–282.

19.	McCarthy, M M., Brooks, P. J., Pfaus, J. G., Brown, H. E., Flanagan, L. M., Schwartz-Giblin, S., and Pfaff, D W (1993) Antisense oligodeoxynucleotides in behavioral neuroscience. Neuroprotocols 2, 64–66.

20.	La Rocca, R.V, Rosenblum, M, Westermark, B., and Israel, M. A (1989) Patterns of protooncogene expression in human glioma cell lines J Neurosci Res 24, 97–106.

21.	Morrison, R.S. (1991) Suppression of basrc tibroblast growth factor expression by antisense oligodeoxynucleotides inhabits the growth of transformed human astrocytes J Biol Chem 266, 728–734.

22.	Bergan, R, Connell, Y, Fahmy, B, and Neckers, L M (1993) Electroporatron enhances c-myc antrsense ohgodeoxynucleotide efficacy Nucleic Acids Res 21, 3567–3573

23.	McManaway, M E, Neckers, L M, Loke, S L, Al-Nasser, A A, Redner, R L, Shiramizu, B T, Goldschmidts, W L, Huber, B E., Bhatra, K., and Magrath, I T (1990) Tumor-specific inhrbition of lymphoma growth by an antisense ohgodeoxynucleotide. Lancet 335, 808–811.

24.	Goodarzr, G, Watabe, M, and Watabe, K (1992) Organ dtstribution and stabihty of phosphorothioated ollgodeoxynucleotides in mice. Biopharm Drug Dispos 13, 22l–227

25.	Inagakr, M, Togawa, K., Carr, B.I., Ghosh, K., and Cohen, J S (1992) Antrsense oligonucleotides inhibition of liver cell prohferation and in vivo disposition Transplant Proc 24, 2971–2972

Comments (Loading...)

Post comment/View all comments